Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Eli Lilly and Novo Nordisk, which respectively sell Mounjaro (tirzepatide) and Ozempic (semaglutide), are leading the GLP-1 space but may face competition from other companies in the coming years
People who are already relatively lean (under 25% body fat for men or under 32% for women) may find that GLP-1 medications produce less dramatic weight loss but still improve body composition through targeted fat reduction
Similarly, Tirzepatide was originally created for the treatment of Type 2 diabetes and has shown significant weight loss potential in clinical trials
In six months, combined with diet and exercise changes, it helped her shed nearly 60 pounds
Gastrointestinal side effects (nausea, diarrhoea, constipation) are common with both treatments and may be compounded when used concurrently
Mechanistic Support
